Top Tweets for #CTOS2018

over 7 years ago

Recently released from #CTOS2018: #sarcoma practice aids available for download now: https://t.co/pIrZioeray #oncology

0

8

5

1

0

over 7 years ago

@DrSarcoma (George Demetri) leads an expert panel in this onDemand CME activity based on a symposium from #CTOS2018 in Rome. Hear about the promise of new concepts and innovative therapy in advanced #sarcoma now. https://t.co/23fifcI5E3 #oncology

0

2

0

over 7 years ago

Hear about integrating innovative therapies into everyday practice for advanced #sarcoma from @DrSarcoma and Drs. George Demetri and Steven DuBois. Access their recent CME symposium from #CTOS2018 online now. https://t.co/23fifcI5E3 #oncology

0

7

5

0

over 7 years ago

Didn't make it to #CTOS2018 in Rome? Access an exciting CME symposium you missed titled "The Promise of New Concepts and Innovative Therapy in Advanced #Sarcoma - From Established Targets to TRK Inhibition and Beyond." https://t.co/23fifcI5E3 #oncology

0

6

4

0

Desmoid Foundation ONLUS - Italia @DesmoidI

over 7 years ago

@DrSarcoma leads an expert panel in this onDemand CME activity based on a symposium from #CTOS2018 in Rome. Hear about the promise of new concepts and innovative therapy in advanced #sarcoma now. https://t.co/23fifcI5E3 #oncology

0

3

0

over 7 years ago

Annual meeting #CTOS2018 in Rome, a really interesting and amazing experience! Thanks to all Doctors for their contribution! @alegronchi @casali_pg @apdeitos @FioreDoc @SilviaStacchia #df #desmoidfoundation #associazioneitalianatumoredesmoide #tumoredesmoide #tumorirari

DesmoidI's tweet photo. Annual meeting #CTOS2018 in Rome, a really interesting and amazing experience! Thanks to all Doctors for their contribution!
@alegronchi @casali_pg @apdeitos @FioreDoc @SilviaStacchia

#df #desmoidfoundation #associazioneitalianatumoredesmoide #tumoredesmoide #tumorirari https://t.co/LwVgsxFR9q

0

20

7

0

George Anadiotis @linked_do

over 7 years ago

My talk on #graphdatabases from #BDS18 is out. New material coming out shortly! Hint: #discountcode #StayTuned #report #newsletter #database #innovation #CTO #ctos2018 #evaluation #Software #usecase #Kudos https://t.co/N5rPw4ukd9

Big Things Conference @BigThingsConf

over 7 years ago

🎥 Missed a talk? Re-watch them all! All the sessions were recorded and are now available for you. Visit our website, and play it now!

BigThingsConf's tweet photo. 🎥 Missed a talk? Re-watch them all! All the sessions were recorded and are now available for you. Visit our website, and play it now!

0

9

3

1

0

2

1

0

Jon Trent, MD, PhD @JTrentMDPhD

over 7 years ago

We test for NTRK fusion in any #GIST patient who is KIT/PDGFR/RAF Wild type and SDH preserved @SylvesterCancer . There is rationale to test all #sarcoma patients who are eligible for systemic therapy at diagnosis presented @ctosociety #ctos2018 by Lara Davis

1

23

11

0

CR Chandrasekar @12crc

over 7 years ago

@sloan_kettering @US_FDA #sarcoma #ctos2018 Impressive results presented at #ctos2018 #Larotrectinib 'TRK fusions occur when one of three genes called the NTRK (pronounced “en-track”) genes becomes mistakenly connected to an unrelated gene. This error can lead to uncontrolled cell growth'

0

5

0

Andy Livingston, MD MS @jalivingston_md

over 7 years ago

@JasonRoszik discusses #NGS to identify potentially targetable alterations in intimal #sarcoma, a rare tumor of large blood vessels at #CTOS2018 Genomically matched therapies may be key to #endcancer https://t.co/6GteTglBMn #PrecisionMedicine @MDAndersonNews @CancerMedMDA

0

3

4

0

CR Chandrasekar @12crc

over 7 years ago

#Sarcoma Another study re.centralisation improves survival (high volume centres performing >20 sarcoma resections/year) from Netherlands #CTOS2018

12crc's tweet photo. #Sarcoma Another study re.centralisation improves survival (high volume centres performing >20 sarcoma resections/year) from Netherlands #CTOS2018 https://t.co/SOzhZs0QJ5

0

1

0

over 7 years ago

Love the int'l study on targeting #leiomyosarcoma pathways, presented at #CTOS2018. "Dysregulation of the p16/RB1 axis occurs in most [soft-tissue] & [gyn] LMS, but only 5% of cases have a biologic profile predictive of benefit from CDK4/6 inhibition. https://t.co/jkeFATJbfS

0

3

1

0

over 7 years ago

Maud Toulmonde @BERGONIE33 & colleagues presented the first study "to assess a comprehensive genomic, transcriptomic, proteomic and immunophenotypic landscape of non pretreated primary" undifferentiated pleomorphic #sarcoma at #CTOS2018. https://t.co/jkeFATJbfS

0

3

0

Seth M. Pollack @immunosarc

over 7 years ago

The international society of pediatric oncology also had interesting presentations on #Ewing #sarcoma. #SIOP2018 I don't have its program, but you can uncover much on the subject by searching the #CTOS2018 program: https://t.co/jkeFATJbfS

0

2

0

over 7 years ago

I must have missed this abstract from @ctos #ctos2018 #pot1 has been linked previously to familial cardiac #angiosarcoma but this was a much broader study. We need better ideas for #screening these patients #Prevention

Sarcoma Alliance @SarcomaAlliance

over 7 years ago

It isn't known why most sarcomas develop - just bad luck? Researchers have now found another gene which appears to increase risk of developing sarcomas. https://t.co/PBNUjhIB71 https://t.co/PBNUjhIB71

2

34

19

0

4

1

0

Pauline Funchain @FunchainMD

over 7 years ago

This was discussed further at #CTOS2018. Search the program for "pexidartinib." #sarcoma https://t.co/jkeFATJbfS

about 8 years ago

ICYMI @ShepardDale reviews pexidartinib, CSF-1 inhibitor, in tenosynovial giant cell tumor = another rationally targeted therapy that works in its molecularly appropriate subgroup #RareDiseases #sarcoma #ASCO18 #CleClinicCancer review

FunchainMD's tweet photo. ICYMI @ShepardDale reviews pexidartinib, CSF-1 inhibitor, in tenosynovial giant cell tumor = another rationally targeted therapy that works in its molecularly appropriate subgroup #RareDiseases #sarcoma #ASCO18 #CleClinicCancer review https://t.co/KNsFCG6Ftc

0

5

1

0

2

0

over 7 years ago

Some women with uterine #leiomyosarcoma get "adjunct chemo" after all the cancer is removed. A study by @Robertasanfili in the #CTOS2018 program suggests anthracycline-based chemo (like doxorubicin) helps more than gemcitabine + docetaxel. https://t.co/jkeFATJbfS

0

5

3

0